Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias
We evaluated incidence of renal adverse events and estimated glomerular filtration rate in patients with Philadelphia chromosome-positive leukemias receiving first-line bosutinib (n=248) or imatinib (n=251), or second-line or later bosutinib (N=570). Results demonstrate that long-term bosutinib treatment is associated with an apparently reversible decline in renal function with frequency and characteristics similar to those observed with long-term imatinib.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Jorge E. Cortes, Carlo Gambacorti-Passerini, Dong-Wook Kim, Hagop M. Kantarjian, Jeff H. Lipton, Amit Lahoti, Moshe Talpaz, Ewa Matczak, Elly Barry, Eric Leip, Tim H. Br ümmendorf, H. Jean Khoury Tags: Original Study Source Type: research